ArticleBMC medical genomics2025
Cost-effective promoter methylation analysis via target long-read bisulfite sequencing: a case study in severe preterm birth.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDNA methylation plays a critical role in the dynamics of gene expression regulation and the development of various disorders. Whole-genome bisulfite sequencing can provide single-base resolution of CpG methylation levels and is the “gold standard” for DNA methylation quantification, but its high cost limits its widespread application. In contrast, targeted sequencing provides an optimal, cost-effective solution when focusing on specific candidate regions while providing sufficient sequencing depth. Here, we present a targeted bisulfite sequencing approach in which nanopore sequencing is used to study the methylation status of regions of interest.
methodsWe applied this workflow to study the promoters of candidate genes associated with severe preterm delivery in a Latin American population. We amplified fragments greater than 1 kilobase in length from 12 genes via long PCR. Each sample was barcoded and pooled for sequencing in MinION flow cells.
resultsThis approach achieves high sequencing depths, ensuring robust DNA methylation (DNAm) estimates. We detected significant hypomethylation of MIR155HG and hypermethylation of the ANKRD24 gene promoter in severe preterm birth samples, which is concordant with previously reported gene expression changes.
conclusionsThis approach represents a scalable and cost-effective method suitable for targeted promoter methylation profiling across several samples. Our study provides a proof-of-concept for larger studies, demonstrating the broad applicability and scalability of our assay to any locus of interest. These features render the method especially apt for clinical diagnostics and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.